These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 31349793)
1. Inhibition of cyclin E1 sensitizes hepatocellular carcinoma cells to regorafenib by mcl-1 suppression. Xu J; Huang F; Yao Z; Jia C; Xiong Z; Liang H; Lin N; Deng M Cell Commun Signal; 2019 Jul; 17(1):85. PubMed ID: 31349793 [TBL] [Abstract][Full Text] [Related]
2. Cyclin E1 Inhibition can Overcome Sorafenib Resistance in Hepatocellular Carcinoma Cells Through Mcl-1 Suppression. Hsu C; Lin LI; Cheng YC; Feng ZR; Shao YY; Cheng AL; Ou DL Clin Cancer Res; 2016 May; 22(10):2555-64. PubMed ID: 26603262 [TBL] [Abstract][Full Text] [Related]
3. STAT3 mediates regorafenib-induced apoptosis in hepatocellular carcinoma. Tai WT; Chu PY; Shiau CW; Chen YL; Li YS; Hung MH; Chen LJ; Chen PL; Su JC; Lin PY; Yu HC; Chen KF Clin Cancer Res; 2014 Nov; 20(22):5768-76. PubMed ID: 25248379 [TBL] [Abstract][Full Text] [Related]
4. Induction of IL-6Rα by ATF3 enhances IL-6 mediated sorafenib and regorafenib resistance in hepatocellular carcinoma. Dai Z; Wang X; Peng R; Zhang B; Han Q; Lin J; Wang J; Lin J; Jiang M; Liu H; Lee TH; Lu KP; Zheng M Cancer Lett; 2022 Jan; 524():161-171. PubMed ID: 34687791 [TBL] [Abstract][Full Text] [Related]
5. LB-100 sensitizes hepatocellular carcinoma cells to the effects of sorafenib during hypoxia by activation of Smad3 phosphorylation. Fu QH; Zhang Q; Zhang JY; Sun X; Lou Y; Li GG; Chen ZL; Bai XL; Liang TB Tumour Biol; 2016 Jun; 37(6):7277-86. PubMed ID: 26666823 [TBL] [Abstract][Full Text] [Related]
6. Dovitinib induces apoptosis and overcomes sorafenib resistance in hepatocellular carcinoma through SHP-1-mediated inhibition of STAT3. Tai WT; Cheng AL; Shiau CW; Liu CY; Ko CH; Lin MW; Chen PJ; Chen KF Mol Cancer Ther; 2012 Feb; 11(2):452-63. PubMed ID: 22180308 [TBL] [Abstract][Full Text] [Related]
7. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312 [TBL] [Abstract][Full Text] [Related]
8. Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells. Wu LW; Zhou DM; Zhang ZY; Zhang JK; Zhu HJ; Lin NM; Zhang C Biochem Biophys Res Commun; 2019 May; 512(4):852-858. PubMed ID: 30929918 [TBL] [Abstract][Full Text] [Related]
9. The cumulative antitumor effects of regorafenib and radiotherapy in hepatocellular carcinoma. Kuang S; Zhang J; Huang N; Zhang J; Chen B; Wang L; Liu M Mol Carcinog; 2024 Sep; 63(9):1738-1749. PubMed ID: 38837427 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of cyclin E1 overcomes temozolomide resistance in glioblastoma by Mcl-1 degradation. Liang H; Chen Z; Sun L Mol Carcinog; 2019 Aug; 58(8):1502-1511. PubMed ID: 31045274 [TBL] [Abstract][Full Text] [Related]
12. Preclinical comparison of regorafenib and sorafenib efficacy for hepatocellular carcinoma using multimodality molecular imaging. Liu S; Du Y; Ma H; Liang Q; Zhu X; Tian J Cancer Lett; 2019 Jul; 453():74-83. PubMed ID: 30928380 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of annexin A3 blockade in sensitizing hepatocellular carcinoma to sorafenib and regorafenib. Tong M; Che N; Zhou L; Luk ST; Kau PW; Chai S; Ngan ES; Lo CM; Man K; Ding J; Lee TK; Ma S J Hepatol; 2018 Oct; 69(4):826-839. PubMed ID: 29885413 [TBL] [Abstract][Full Text] [Related]
14. Molecularly targeted anti-cancer drugs inhibit the invasion and metastasis of hepatocellular carcinoma by regulating the expression of MMP and TIMP gene families. He XX; Shi LL; Qiu MJ; Li QT; Wang MM; Xiong ZF; Yang SL Biochem Biophys Res Commun; 2018 Oct; 504(4):878-884. PubMed ID: 30219235 [TBL] [Abstract][Full Text] [Related]
15. Regorafenib reverses HGF-induced sorafenib resistance by inhibiting epithelial-mesenchymal transition in hepatocellular carcinoma. Chen W; Yang J; Zhang Y; Cai H; Chen X; Sun D FEBS Open Bio; 2019 Feb; 9(2):335-347. PubMed ID: 30761258 [TBL] [Abstract][Full Text] [Related]
16. Regorafenib inhibits tumor progression through suppression of ERK/NF-κB activation in hepatocellular carcinoma bearing mice. Weng MC; Wang MH; Tsai JJ; Kuo YC; Liu YC; Hsu FT; Wang HE Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29535278 [TBL] [Abstract][Full Text] [Related]
17. Combined treatment with sorafenib and silibinin synergistically targets both HCC cells and cancer stem cells by enhanced inhibition of the phosphorylation of STAT3/ERK/AKT. Mao J; Yang H; Cui T; Pan P; Kabir N; Chen D; Ma J; Chen X; Chen Y; Yang Y Eur J Pharmacol; 2018 Aug; 832():39-49. PubMed ID: 29782854 [TBL] [Abstract][Full Text] [Related]
18. Mcl-1 inhibition overcomes intrinsic and acquired regorafenib resistance in colorectal cancer. Song X; Shen L; Tong J; Kuang C; Zeng S; Schoen RE; Yu J; Pei H; Zhang L Theranostics; 2020; 10(18):8098-8110. PubMed ID: 32724460 [TBL] [Abstract][Full Text] [Related]
19. PMPCB Silencing Sensitizes HCC Tumor Cells to Sorafenib Therapy. Zheng JF; He S; Zeng Z; Gu X; Cai L; Qi G Mol Ther; 2019 Oct; 27(10):1784-1795. PubMed ID: 31337603 [TBL] [Abstract][Full Text] [Related]
20. Restoration of miR-193b sensitizes Hepatitis B virus-associated hepatocellular carcinoma to sorafenib. Mao K; Zhang J; He C; Xu K; Liu J; Sun J; Wu G; Tan C; Zeng Y; Wang J; Xiao Z Cancer Lett; 2014 Oct; 352(2):245-52. PubMed ID: 25034398 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]